Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -13.98% | -53.70% | |||
| Total Depreciation and Amortization | 3,200.00% | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -69.57% | 242.00% | |||
| Change in Net Operating Assets | 239.44% | 228.51% | |||
| Cash from Operations | -18.66% | 17.64% | |||
| Capital Expenditure | 90.71% | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | 1,355.00% | -- | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -99.81% | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -105.22% | -365.79% | |||
| Cash from Financing | -99.91% | -367.36% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -113.48% | -94.77% | |||